<?xml version="1.1" encoding="utf-8"?>
<article xsi:noNamespaceSchemaLocation="http://jats.nlm.nih.gov/publishing/1.1/xsd/JATS-journalpublishing1-mathml3.xsd" dtd-version="1.1" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><front><journal-meta><journal-id journal-id-type="publisher-id">JCNR</journal-id><journal-title-group><journal-title>Journal of Clinical and Nursing Research</journal-title></journal-title-group><issn>2208-3685</issn><eissn>2208-3693</eissn><publisher><publisher-name>Bio-Byword Scientific Publishing Pty. Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.26689/jcnr.v9i9.12278</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title>Analysis of the Clinical Efficacy of Recombinant Human Interferon α2b Nebulization Inhalation in the Treatment of Hand, Foot, and Mouth Disease in Children</title><url>https://artdesignp.com/journal/JCNR/9/9/10.26689/jcnr.v9i9.12278</url><author>YangXia</author><pub-date pub-type="publication-year"><year>2025</year></pub-date><volume>9</volume><issue>9</issue><history><date date-type="pub"><published-time>2025-10-16</published-time></date></history><abstract>This clinical study aimed to explore the therapeutic effect of recombinant human interferon α2b nebulization inhalation in the treatment of hand, foot, and mouth disease in children. Sixty-six patients were selected as the research subjects by the random sampling method and divided into a control group and an observation group. The patients in the control group were treated with ribavirin injection and oral lysine-inositol-vitamin B12 solution, while the patients in the observation group received the treatment of the control group combined with recombinant human interferon α2b nebulization inhalation. The clinical effects of the two groups were compared to determine the clinical efficacy of the two treatment plans. The total effective rates of treatment were 78.79% in the control group and 90.91% in the observation group. The research confirmed that the clinical effect of recombinant human interferon α2b nebulization inhalation in the treatment of hand, foot, and mouth disease in children is remarkable. It can significantly improve the symptoms of children with hand, foot, and mouth disease and is suitable for clinical application and promotion.</abstract><keywords/></article-meta></front><body/><back><ref-list><ref id="B1" content-type="article"><label>1</label><element-citation publication-type="journal"><p>Zhang A, Guo C, Yang Z, 2023, Clinical Efficacy of Interferon Nebulization Inhalation in Children with Hand, Foot, and Mouth Disease and Its Effects on Inflammatory Factors and Immune Function. Clinical Research, 31(12): 53–56.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B2" content-type="article"><label>2</label><element-citation publication-type="journal"><p>Zeng X, Han X, 2022, Clinical Efficacy of Interferon Nebulization Inhalation in Children with Hand, Foot, and Mouth Disease and Its Effects on Inflammatory Factor Levels. Laboratory Medicine and Clinic, 19(22): 3129–3131.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B3" content-type="article"><label>3</label><element-citation publication-type="journal"><p>Zhu H, Zhang Y, 2021, Efficacy of Recombinant Human Interferon α-2b Nebulization Inhalation in Treating Hand, Foot, and Mouth Disease in Children. Systems Medicine, 6(18): 129–131.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B4" content-type="article"><label>4</label><element-citation publication-type="journal"><p>Chen M, Chen F, Zhang S, 2021, Efficacy of Different Doses of Recombinant Human Interferon α-1b Nebulization Inhalation in Treating Severe Hand, Foot, and Mouth Disease in Children. Clinical Medical Engineering, 28(06): 745–746.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B5" content-type="article"><label>5</label><element-citation publication-type="journal"><p>Li N, 2021, Effect of Interferon Nebulization Inhalation on Oral Herpes Children with Hand, Foot, and Mouth Disease. Contemporary Nurse (Upper Edition), 28(05): 110–111.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B6" content-type="article"><label>6</label><element-citation publication-type="journal"><p>Gao N, Yue J, Li S, et al., 2021, Efficacy Analysis of Recombinant Human Interferon α-2b Nebulization in Treating Hand, Foot, and Mouth Disease in Children. Chinese Journal of Clinical Practical Medicine, 12(03): 52–56.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B7" content-type="article"><label>7</label><element-citation publication-type="journal"><p>Li Y, Zhang X, Cen J, 2019, Efficacy of Nebulized Recombinant Human Interferon α2b in Children with Hand, Foot, and Mouth Disease and Its Effect on Serum Inflammatory Factors. Chinese Journal of Rational Drug Use, 2019(11): 4.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B8" content-type="article"><label>8</label><element-citation publication-type="journal"><p>Zhang J, Xu J, Zhang W, et al., 2023, Efficacy of Qingre Xiaodu Decoction Combined with Recombinant Human Interferon α2b Spray in Treating Hand, Foot, and Mouth Disease in Children. Hubei Journal of Traditional Chinese Medicine, 45(9): 15–17.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B9" content-type="article"><label>9</label><element-citation publication-type="journal"><p>Xu S, 2024, Clinical Effect of Recombinant Human Interferon α2b Nebulization Inhalation in Treating Hand, Foot, and Mouth Disease in Children. Guide to Women and Children’s Health, 3(3): 64–67.</p><pub-id pub-id-type="doi"/></element-citation></ref><ref id="B10" content-type="article"><label>10</label><element-citation publication-type="journal"><p>Lian L, Gao J, Wang S, et al., 2024, Clinical Efficacy of Compound Yinhua Jiedu Granules Combined with Recombinant Human Interferon α-2b Spray in Treating Hand, Foot, and Mouth Disease and Its Effect on Inflammatory Indicators. Smart Healthcare, 10(36): 72–75.</p><pub-id pub-id-type="doi"/></element-citation></ref></ref-list></back></article>
